Overview
Browse spinoutsLegal name
IMOPHORON LIMITED
Region
South West England
Registered address
Unknown
Insolvency history
No
Spinout
Active
LTD
Company profile
Imophoron Limited
Imophoron | Next Generation Vaccines | ADDomer | England
Imophoron's technology is right at the forefront of cutting edge vaccine development. We are constantly looking for new and innovative ways to combat infection using the very latest thechniques from science and technology. Full details can be found at www.imophoron.com.
CRN
11096893
Founded
2017
Age
8
Latest accounts
Financial period: 1 Jan 2024 to 31 Dec 2024
FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
9
Company events
Reference milestones and recent Companies House filing stream events.
6 events
18 Nov
2024
Appoint Person Secretary Company With Name Date
OfficersAP03 | Transaction MzQ0MzY4NzMwMmFkaXF6a2N4
Published 18 Nov 2024 10:07
18 Nov
2024
Termination Secretary Company With Name Termination Date
OfficersTM02 | Transaction MzQ0MzY4Njg5MGFkaXF6a2N4
Published 18 Nov 2024 10:05
18 Nov
2024
Termination Director Company With Name Termination Date
OfficersTM01 | Transaction MzQ0MzY4Njc0N2FkaXF6a2N4
Published 18 Nov 2024 10:04
25 Sep
2024
Appoint Person Director Company With Name Date
OfficersAP01 | Transaction MzQzNzE4NjM4M2FkaXF6a2N4
Published 25 Sep 2024 11:40
25 Sep
2024
Termination Director Company With Name Termination Date
OfficersTM01 | Transaction MzQzNzE4NTcwMGFkaXF6a2N4
Published 25 Sep 2024 11:34
05 Dec
2017
Incorporated
InceptionCompany registered at Companies House
Spinout profile
5 entries
Company description
Imophoron develops a range of therapeutics.
Novel vaccine platform technology company
Project impact
Press release issued: 7 October 2021 Faster vaccine development could be a step closer thanks to £4 million investment to Imophoron Ltd, a Bristol University biotech start-up developing a novel, next generation rapid-response vaccine platform called ADDomer™. Imophoron will use the investment to bring ADDomer vaccines to clinical stage, initially targeting three viruses, RSV (respiratory syncytial virus), COVID-19, and mosquito-borne Chikungunya.
Not yet evaluated.
None yet
Imophoron
2017
Imophoron
2017
Imophoron
2017
Imophoron
2017
IMOPHORON LIMITED
2017
Public funding
1 award
First funded
2024
Funded years
2024
Age at first award
6 years
Projects
2024
Collaborative R&D
Lead participant
Feasibility of Intranasal Delivery for Novel Nanoparticle-Based Vaccines
1 Sep 2024 to 31 Jan 2025
Awarded
£99,962
Total cost £142,803
Vaccines have been instrumental in driving material advancements in global health throughout the modern medical era. Intranasal administration of vaccines is an attractive alternative to injections for multiple reasons: * Eliminating needles can reduce anxiety for patients with needle fear or needle fatigue, especially children and those with chronic cond...
Product types
Collaborative R&D